BioPorto A/S
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the onset of disease states for management and therapies in Europe, North America, Asia, and internationally. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neu… Read more
BioPorto A/S (THOXF) - Net Assets
Latest net assets as of June 2025: $57.22 Million USD
Based on the latest financial reports, BioPorto A/S (THOXF) has net assets worth $57.22 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($88.03 Million) and total liabilities ($30.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $57.22 Million |
| % of Total Assets | 65.0% |
| Annual Growth Rate | N/A |
| 5-Year Change | -32.83% |
| 10-Year Change | 52.36% |
| Growth Volatility | 89.52 |
BioPorto A/S - Net Assets Trend (2005–2024)
This chart illustrates how BioPorto A/S's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BioPorto A/S (2005–2024)
The table below shows the annual net assets of BioPorto A/S from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $67.78 Million | +12.66% |
| 2023-12-31 | $60.16 Million | -14.33% |
| 2022-12-31 | $70.22 Million | +52.77% |
| 2021-12-31 | $45.96 Million | -54.45% |
| 2020-12-31 | $100.91 Million | +298.52% |
| 2019-12-31 | $25.32 Million | -54.94% |
| 2018-12-31 | $56.20 Million | +0.23% |
| 2017-12-31 | $56.07 Million | +26.59% |
| 2016-12-31 | $44.29 Million | -0.44% |
| 2015-12-31 | $44.48 Million | +55.08% |
| 2014-12-31 | $28.69 Million | -31.06% |
| 2013-12-31 | $41.61 Million | +3718.43% |
| 2012-12-31 | $-1.15 Million | -129.20% |
| 2011-12-31 | $3.94 Million | +19.04% |
| 2010-12-31 | $3.31 Million | -78.53% |
| 2009-12-31 | $15.41 Million | -0.59% |
| 2008-12-31 | $15.50 Million | -47.37% |
| 2007-12-31 | $29.45 Million | +267.20% |
| 2006-12-31 | $-17.62 Million | -476.47% |
| 2005-12-31 | $-3.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioPorto A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28403400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $429.67 Million | 633.94% |
| Total Equity | $67.78 Million | 100.00% |
BioPorto A/S Competitors by Market Cap
The table below lists competitors of BioPorto A/S ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Locaweb Serviços de Internet S.A.
SA:LWSA3
|
$130.33 Million |
|
Innova Captab Limited
NSE:INNOVACAP
|
$130.37 Million |
|
Zalaris ASA
OL:ZAL
|
$130.41 Million |
|
CERENO SCIENTIFIC AB B
F:4A1
|
$130.44 Million |
|
Kis Wire
KO:002240
|
$130.32 Million |
|
Camlin Fine Sciences Limited
NSE:CAMLINFINE
|
$130.29 Million |
|
CCFNB Bancorp Inc
OTCQX:CCFN
|
$130.27 Million |
|
Sariguna Primatirta PT
JK:CLEO
|
$130.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioPorto A/S's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 60,160,000 to 67,778,000, a change of 7,618,000 (12.7%).
- Net loss of 68,243,000 reduced equity.
- New share issuances of 81,400,000 increased equity.
- Other comprehensive income decreased equity by 225,000.
- Other factors decreased equity by 5,314,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-68.24 Million | -100.69% |
| Share Issuances | $81.40 Million | +120.1% |
| Other Comprehensive Income | $-225.00K | -0.33% |
| Other Changes | $-5.31 Million | -7.84% |
| Total Change | $- | 12.66% |
Book Value vs Market Value Analysis
This analysis compares BioPorto A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.72x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $-0.08 | $0.29 | x |
| 2006-12-31 | $-0.43 | $0.29 | x |
| 2007-12-31 | $0.56 | $0.29 | x |
| 2008-12-31 | $0.24 | $0.29 | x |
| 2009-12-31 | $0.24 | $0.29 | x |
| 2010-12-31 | $0.05 | $0.29 | x |
| 2011-12-31 | $0.05 | $0.29 | x |
| 2012-12-31 | $-0.02 | $0.29 | x |
| 2013-12-31 | $0.53 | $0.29 | x |
| 2014-12-31 | $0.24 | $0.29 | x |
| 2015-12-31 | $0.37 | $0.29 | x |
| 2016-12-31 | $0.34 | $0.29 | x |
| 2017-12-31 | $0.39 | $0.29 | x |
| 2018-12-31 | $0.36 | $0.29 | x |
| 2019-12-31 | $0.15 | $0.29 | x |
| 2020-12-31 | $0.49 | $0.29 | x |
| 2021-12-31 | $0.17 | $0.29 | x |
| 2022-12-31 | $0.22 | $0.29 | x |
| 2023-12-31 | $0.17 | $0.29 | x |
| 2024-12-31 | $0.17 | $0.29 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioPorto A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -100.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -188.29%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.42x
- Recent ROE (-100.69%) is above the historical average (-105.71%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 0.00% | -342.89% | 0.30x | 0.00x | $-14.65 Million |
| 2006 | 0.00% | -283.17% | 1.16x | 0.00x | $-13.97 Million |
| 2007 | -48.43% | -171.03% | 0.25x | 1.15x | $-17.21 Million |
| 2008 | -95.10% | -176.76% | 0.44x | 1.24x | $-16.29 Million |
| 2009 | -103.52% | -144.93% | 0.54x | 1.31x | $-17.50 Million |
| 2010 | -429.34% | -102.93% | 0.66x | 6.34x | $-14.54 Million |
| 2011 | -376.60% | -79.84% | 0.87x | 5.39x | $-15.23 Million |
| 2012 | 0.00% | -82.32% | 0.98x | 0.00x | $-14.59 Million |
| 2013 | -52.56% | -131.57% | 0.33x | 1.22x | $-26.03 Million |
| 2014 | -45.06% | -69.10% | 0.50x | 1.30x | $-15.79 Million |
| 2015 | -24.12% | -52.65% | 0.42x | 1.10x | $-15.18 Million |
| 2016 | -51.48% | -110.04% | 0.41x | 1.14x | $-27.23 Million |
| 2017 | -57.51% | -128.18% | 0.38x | 1.17x | $-37.85 Million |
| 2018 | -67.70% | -146.25% | 0.39x | 1.18x | $-43.67 Million |
| 2019 | -275.03% | -261.60% | 0.62x | 1.69x | $-72.17 Million |
| 2020 | -61.01% | -265.31% | 0.17x | 1.39x | $-71.65 Million |
| 2021 | -124.26% | -235.48% | 0.30x | 1.77x | $-61.71 Million |
| 2022 | -108.12% | -262.08% | 0.27x | 1.55x | $-82.95 Million |
| 2023 | -93.63% | -181.95% | 0.34x | 1.49x | $-62.34 Million |
| 2024 | -100.69% | -188.29% | 0.38x | 1.42x | $-75.02 Million |
Industry Comparison
This section compares BioPorto A/S's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioPorto A/S (THOXF) | $57.22 Million | 0.00% | 0.54x | $130.33 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |